Impact of receiving recorded mental health recovery narratives on quality of life in people experiencing psychosis, people experiencing other mental health problems and for informal carers: Narrative Experiences Online (NEON) study protocol for three randomised controlled trials.
Carers
MANSA
Mental health
Pragmatic trial
Psychosis
Quality of life
Randomised controlled trial
Recovery narratives
Recovery stories
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
20 Jul 2020
20 Jul 2020
Historique:
received:
13
03
2020
accepted:
17
05
2020
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
14
5
2021
Statut:
epublish
Résumé
Mental health recovery narratives have been defined as first-person lived experience accounts of recovery from mental health problems which refer to events or actions over a period of time and which include elements of adversity or struggle, and also self-defined strengths, successes or survival. They are readily available in invariant recorded form, including text, audio or video. Previous studies have provided evidence that receiving recorded recovery narratives can provide benefits to recipients. This protocol describes three pragmatic trials that will be conducted by the Narrative Experiences Online (NEON) study using the NEON Intervention, a web application that delivers recorded recovery narratives to its users. The aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON Intervention benefits people with experience of psychosis. The aim of the NEON-O and NEON-C trials is to evaluate the feasibility of conducting a definitive trial on the use of the NEON Intervention with people experiencing non-psychosis mental health problems and those who care for others experiencing mental health problems respectively. The NEON Trial will recruit 683 participants with experience of psychosis. The NEON-O Trial will recruit at least 100 participants with experience of non-psychosis mental health problems. The NEON-C Trial will recruit at least 100 participants with experience of caring for others who have experienced mental health problems. In all three trials, participants will be randomly allocated into one of two arms. Intervention arm participants will receive treatment as usual plus immediate access to the NEON Intervention for 1 year. Control arm participants will receive treatment as usual plus access to the NEON Intervention after 1 year. All participants will complete demographics and outcome measures at baseline, 1 week, 12 weeks and 52 weeks. For the NEON Trial, the primary outcome measure is the Manchester Short Assessment of Quality of Life at 52 weeks, and secondary outcome measures are the CORE-10, Herth Hope Index, Mental Health Confidence Scale and Meaning in Life Questionnaire. A cost-effectiveness analysis will be conducted using data collected through the EQ-5D-5 L and the Client Service Receipt Inventory. NEON Trial analyses will establish both effectiveness and cost-effectiveness of the NEON Intervention for people with experience of psychosis, and hence inform future clinical recommendations for this population. All trials were prospectively registered with ISRCTN. NEON Trial: ISRCTN11152837 . Registered on 13 August 2018. NEON-C Trial: ISRCTN76355273 . Registered on 9 January 2020. NEON-O Trial: ISRCTN63197153 . Registered on 9 January 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Mental health recovery narratives have been defined as first-person lived experience accounts of recovery from mental health problems which refer to events or actions over a period of time and which include elements of adversity or struggle, and also self-defined strengths, successes or survival. They are readily available in invariant recorded form, including text, audio or video. Previous studies have provided evidence that receiving recorded recovery narratives can provide benefits to recipients. This protocol describes three pragmatic trials that will be conducted by the Narrative Experiences Online (NEON) study using the NEON Intervention, a web application that delivers recorded recovery narratives to its users. The aim of the NEON Trial is to understand whether receiving online recorded recovery narratives through the NEON Intervention benefits people with experience of psychosis. The aim of the NEON-O and NEON-C trials is to evaluate the feasibility of conducting a definitive trial on the use of the NEON Intervention with people experiencing non-psychosis mental health problems and those who care for others experiencing mental health problems respectively.
METHODS
METHODS
The NEON Trial will recruit 683 participants with experience of psychosis. The NEON-O Trial will recruit at least 100 participants with experience of non-psychosis mental health problems. The NEON-C Trial will recruit at least 100 participants with experience of caring for others who have experienced mental health problems. In all three trials, participants will be randomly allocated into one of two arms. Intervention arm participants will receive treatment as usual plus immediate access to the NEON Intervention for 1 year. Control arm participants will receive treatment as usual plus access to the NEON Intervention after 1 year. All participants will complete demographics and outcome measures at baseline, 1 week, 12 weeks and 52 weeks. For the NEON Trial, the primary outcome measure is the Manchester Short Assessment of Quality of Life at 52 weeks, and secondary outcome measures are the CORE-10, Herth Hope Index, Mental Health Confidence Scale and Meaning in Life Questionnaire. A cost-effectiveness analysis will be conducted using data collected through the EQ-5D-5 L and the Client Service Receipt Inventory.
DISCUSSION
CONCLUSIONS
NEON Trial analyses will establish both effectiveness and cost-effectiveness of the NEON Intervention for people with experience of psychosis, and hence inform future clinical recommendations for this population.
TRIAL REGISTRATION
BACKGROUND
All trials were prospectively registered with ISRCTN. NEON Trial: ISRCTN11152837 . Registered on 13 August 2018. NEON-C Trial: ISRCTN76355273 . Registered on 9 January 2020. NEON-O Trial: ISRCTN63197153 . Registered on 9 January 2020.
Identifiants
pubmed: 32690105
doi: 10.1186/s13063-020-04428-6
pii: 10.1186/s13063-020-04428-6
pmc: PMC7370499
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
661Subventions
Organisme : Department of Health
ID : RP-PG-0615-20016
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : RP-PG-0615-20016
Références
J Med Internet Res. 2016 May 16;18(5):e97
pubmed: 27185295
Psychol Med. 2015 Jan;45(1):11-27
pubmed: 24569086
J Adv Nurs. 1992 Oct;17(10):1251-9
pubmed: 1430629
JMIR Ment Health. 2018 May 08;5(2):e37
pubmed: 29739737
J Clin Epidemiol. 2017 Oct;90:92-98
pubmed: 28694123
Aust N Z J Psychiatry. 2006 Nov-Dec;40(11-12):972-80
pubmed: 17054565
JAMA. 1996 Aug 28;276(8):637-9
pubmed: 8773637
J Med Internet Res. 2010 Dec 19;12(5):e70
pubmed: 21169176
J Hum Reprod Sci. 2011 Jan;4(1):8-11
pubmed: 21772732
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Behav Res Ther. 2015 Jan;64:24-30
pubmed: 25499927
Epidemiol Psychiatr Sci. 2018 Oct;27(5):413-414
pubmed: 29644948
Psychiatr Rehabil J. 2016 Sep;39(3):211-21
pubmed: 27618458
Schizophr Res. 2014 Jun;156(1):96-106
pubmed: 24746468
Lancet. 2016 Mar 12;387(10023):1123-1132
pubmed: 26410341
J Empir Res Hum Res Ethics. 2016 Jul;11(3):274-80
pubmed: 27329533
Schizophr Res. 2013 Jan;143(1):143-9
pubmed: 23146146
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD004807
pubmed: 23543537
Behav Cogn Psychother. 2016 Jan;44(1):65-78
pubmed: 25430776
J Anxiety Disord. 2009 Mar;23(2):185-96
pubmed: 18676121
Psychiatr Serv. 2010 Mar;61(3):321-4
pubmed: 20194414
J Nerv Ment Dis. 2015 Aug;203(8):591-5
pubmed: 26230647
Issues Ment Health Nurs. 2011;32(2):98-107
pubmed: 21247275
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Community Ment Health J. 2013 Jun;49(3):344-53
pubmed: 23179046
Arch Gen Psychiatry. 1996 Nov;53(11):1022-31
pubmed: 8911225
Emotion. 2015 Aug;15(4):484-93
pubmed: 26098734
J Clin Psychol. 1999 Oct;55(10):1243-54
pubmed: 11045774
Sociol Health Illn. 2004 Mar;26(2):242-61
pubmed: 15027986
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
World Psychiatry. 2014 Feb;13(1):4-11
pubmed: 24497236
Pharmacoeconomics. 2013 May;31(5):361-7
pubmed: 23529207
Psychother Psychosom. 2015;84(5):304-13
pubmed: 26278784
Psychiatr Serv. 2008 Nov;59(11):1338-42
pubmed: 18971413
Int J Soc Psychiatry. 1999 Spring;45(1):7-12
pubmed: 10443245
Aust J Rural Health. 2007 Apr;15(2):81-7
pubmed: 17441815
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
JMIR Ment Health. 2019 Oct 4;6(10):e14233
pubmed: 31588912
Br J Psychiatry. 2007 Nov;191:420-6
pubmed: 17978322
J Psychiatr Ment Health Nurs. 2009 Feb;16(1):68-75
pubmed: 19192088
J Ment Health. 2015 Apr;24(2):73-7
pubmed: 25356521
Soc Sci Med. 2011 Jan;72(1):54-62
pubmed: 21112682
BMC Psychiatry. 2019 Dec 21;19(1):413
pubmed: 31864315
J Behav Ther Exp Psychiatry. 2018 Dec;61:134-141
pubmed: 30077703
Can J Psychiatry. 2019 Oct;64(10):669-679
pubmed: 31046432
Pharmacoeconomics. 2008;26(10):847-60
pubmed: 18793032
Int J Soc Psychiatry. 2013 Aug;59(5):493-500
pubmed: 22532125
Curr Opin Psychiatry. 2014 Jul;27(4):276-81
pubmed: 24852058
Qual Health Res. 2017 Jan;27(2):285-294
pubmed: 26825480
JMIR Ment Health. 2020 Sep 18;7(9):e16290
pubmed: 32945771
JAMA Psychiatry. 2015 Jul;72(7):697-705
pubmed: 26018466
Epidemiol Psychiatr Sci. 2015 Oct;24(5):435-45
pubmed: 24992284
Control Clin Trials. 1988 Dec;9(4):327-44
pubmed: 3203524
Psychiatry Res. 2012 Aug 15;198(3):395-9
pubmed: 22425469
Int J Soc Psychiatry. 2014 Mar;60(2):148-54
pubmed: 23399990
World Psychiatry. 2012 Jun;11(2):123-8
pubmed: 22654945
BMC Public Health. 2012 Jun 28;12:489
pubmed: 22742085
Pharmacoeconomics. 1999 May;15(5):423-34
pubmed: 10537960
Schizophr Bull. 2001;27(2):187-95
pubmed: 11354586
Soc Psychiatry Psychiatr Epidemiol. 2000 Feb;35(2):78-85
pubmed: 10784370
J Clin Psychol. 2011 Dec;67(12):1210-9
pubmed: 22068974
Br J Psychiatry. 2017 Nov;211(5):316-322
pubmed: 28935661
J Psychiatr Ment Health Nurs. 2006 Oct;13(5):490-7
pubmed: 16965466
PLoS One. 2019 Mar 28;14(3):e0214678
pubmed: 30921432
Br J Psychiatry. 2011 Dec;199(6):445-52
pubmed: 22130746
Med Care. 2001 Nov;39(11):1217-23
pubmed: 11606875
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476
BMC Med Res Methodol. 2013 Jun 13;13:78
pubmed: 23758922
Soc Psychiatry Psychiatr Epidemiol. 2020 Mar;55(3):295-308
pubmed: 31654089
BMC Psychiatry. 2018 Apr 13;18(1):102
pubmed: 29653532
BMJ Open. 2019 Jan 3;9(1):e027583
pubmed: 30610027
PLoS One. 2019 Dec 13;14(12):e0226201
pubmed: 31834902
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663
BMJ Open. 2019 Jun 28;9(6):e029342
pubmed: 31256037
Int J Soc Psychiatry. 2011 Sep;57(5):446-54
pubmed: 20378660
Int J Soc Psychiatry. 2015 Feb;61(1):92-101
pubmed: 25381145